Portside Wealth Group, LLC Halozyme Therapeutics, Inc. Transaction History
Portside Wealth Group, LLC
- $586 Billion
- Q3 2024
A detailed history of Portside Wealth Group, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Portside Wealth Group, LLC holds 9,123 shares of HALO stock, worth $521,379. This represents 0.09% of its overall portfolio holdings.
Number of Shares
9,123
Previous 3,931
132.08%
Holding current value
$521,379
Previous $206 Million
153.71%
% of portfolio
0.09%
Previous 0.04%
Shares
4 transactions
Others Institutions Holding HALO
# of Institutions
512Shares Held
124MCall Options Held
208KPut Options Held
77.1K-
Black Rock Inc. New York, NY17.6MShares$1.01 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$736 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$332 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$231 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$212 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.96B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...